TPWA
NRIX icon

Twin Peaks Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16 Buy
+1
New +$17 ﹤0.01% 2353
2025
Q3 		– Sell
-1
Closed -$10 – 1437
2025
Q2 		$10 Buy
+1
New +$11 ﹤0.01% 2267

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Twin Peaks Wealth Advisors's NRIX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 1 share worth $16. The stake represents ﹤0.01% of the portfolio and ranks #2353 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in NRIX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in NRIX in Q2 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 1 share of Nurix Therapeutics worth $16 as of Q1 2026.
  • Nurix Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2353 holding.
  • Twin Peaks Wealth Advisors first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.